What is Matter?
Founded in 2015, Matter operates as a premier healthcare incubator and collaborative workspace headquartered in Chicago, Illinois. The company functions as a nexus for innovation, connecting startups with a robust network of hospitals, health systems, universities, and industry-leading corporations. By providing a structured environment for cross-sector partnership, Matter accelerates the development of transformative health solutions. Its market position is unique; rather than focusing solely on individual product development, the company cultivates an entire ecosystem designed to improve patient outcomes and streamline the delivery of care through collaborative synergy.
How much funding has Matter raised?
Matter has raised a total of $39.4M across 2 funding rounds:
Unspecified
$4.4M
Series A
$35M
Unspecified (2014): $4.4M with participation from AbbVie Inc., Astellas Pharma, and Marathon Pharmaceuticals, LLC
Series A (2022): $35M led by Jordan Park Group
Key Investors in Matter
AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions that address some of the worlds most complex medical challenges.
Astellas Pharma
Astellas Pharma is engaged in the manufacturing, marketing, import, and export of pharmaceuticals. It is headquartered in Tokyo, Japan.
Marathon Pharmaceuticals, LLC
Marathon Pharmaceuticals, LLC, is a biopharmaceutical company that develops treatments for rare diseases, with a focus on patients who currently have no treatment options.
What's next for Matter?
With the successful closure of this latest financing round, Matter is well-positioned to expand its operational footprint and deepen its engagement with global health systems. The strategic focus will likely shift toward scaling its digital health initiatives and enhancing the technological infrastructure required to support its growing cohort of startups. As the healthcare landscape faces increasing pressure to modernize, Matter's role as a facilitator of innovation becomes even more critical. The organization is expected to leverage this capital to broaden its international reach, fostering deeper partnerships that bridge the gap between research-driven biopharma and agile, tech-forward medical solutions.
See full Matter company page
